| Project/Area Number |
16K11518
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Meikai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
関根 圭輔 横浜市立大学, 医学部, 講師 (00323569)
|
|---|
| Project Period (FY) |
2016-10-21 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 破骨細胞 / ＣＤ１３ / Fibronectin / NGR配列 / がん細胞 / ＨＴ１０８０ / CD13 / HT1080 / 歯学 / 細菌 / 免疫学 / 発生・分化 / シグナル伝達 |
|---|
| Outline of Final Research Achievements |
We found that N-terminal peptide A of fibronectin (Patent application 2019-115222) enhances osteoclast formation via internalization of peptide A-CD13 complex into osteoclast progenitor cells and induces apoptosis of human fibrosarcoma HT1080 highly expressing CD13 via DNA binding in nuclear. Furthermore we tried to prepare R-Etodolac- or Dox-combined peptide A to examine the drug delivery activity of it. Dox-combined peptide A was accumulated in solid tumors of HT-1080 implanted-BALB/c nude mice, and inhibited the growth. Peptide A have anti-tumor activity and tumor specific drug delivery activity.
|
| Academic Significance and Societal Importance of the Research Achievements |
CVCTGNGRGEWKC、GNGRGEW、CNGRC (S-S環状化)のペプチドには、破骨細胞前駆細胞機能維持活性は認められなかったが、ペプチドＡ（特願2019-115222)にその活性が認められた。さらに、CD13高発現ヒト線維肉腫由来HT-1080細胞に対する抗がん作用も同様にペプチドＡにのみその活性が認められた。このペプチドＡの抗がん活性は、正常細胞である破骨細胞前駆細胞株4B12細胞とヒトGin-1細胞では認められなかった。このことは、ペプチドＡが新規抗がん剤として有効である可能性が出てきたことは、学術的・社会的意義は大きいと考える。
|
